Skip to main content

A Blinded Longterm Ext Study to Eval the Safety and Efficacy of Pioglitazone (AD-4833 Sust Release 0.8 mg daily) to Slow the Progress of Cog Decline in Subj Who Have completed the AD4833/TOMM40_301 Study w/ Diag of Mild Cog Impair due to Alz Disease.

Clinical Trial Grant
Duke Scholars

Administered By

Neurology, Behavioral Neurology

Awarded By

Takeda Pharmaceuticals North America Inc.

Start Date

April 1, 2015

End Date

December 31, 2019
 

Administered By

Neurology, Behavioral Neurology

Awarded By

Takeda Pharmaceuticals North America Inc.

Start Date

April 1, 2015

End Date

December 31, 2019